Physician profile
Erin Eileen Yard
NPI 1114400165
$5,092.29
in general payments reported to CMS, 2019-2025
25 companies · $812 in 2025
The $812 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $891 · 2022: $1,218 · 2023: $1,304 · 2024: $868 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.15 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,716.13 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $804.90 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $522.50 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $459.39 | 2021-2025 | Entyvio |
| Genzyme Corporation | $234.97 | 2022-2025 | |
| Madrigal Pharmaceuticals | $217.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $196.70 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $140.30 | 2021-2023 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $99.41 | 2022 | |
| Janssen Scientific Affairs, LLC | $91.98 | 2022 | |
| Amgen INC. | $86.27 | 2022-2023 | Avsola, Amjevita |
| Pfizer INC. | $81.89 | 2023-2024 | |
| Lilly USA, LLC | $78.02 | 2023-2025 | Omvoh |
| Celgene Corporation | $70.68 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $52.92 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $44.16 | 2021 | |
| Ardelyx, INC. | $40.68 | 2022-2025 | Ibsrela |
| Vivus LLC | $31.44 | 2021-2025 | Qsymia |
| Ipsen Biopharmaceuticals, INC | $26.03 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $24.63 | 2024 | Dificid |
| Sandoz INC. | $20.05 | 2023 | Hyrimoz |
| Organon LLC | $14.54 | 2025 | Hadlima, Renflexis |
| Phathom Pharmaceuticals, INC. | $13.61 | 2024 | Voquezna |
| Evoke Pharma, INC. | $12.01 | 2021 | |
| Daiichi Sankyo INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Yard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.